Immunodiagnosis of childhood ALL with monoclonal antibodies to myeloid and lymphoid associated antigens.
Sixty-five cryopreserved leukemic samples from children diagnosed and treated as having acute lymphocytic leukemia (ALL) were retrospectively examined for the presence of lymphoid and myeloid associated antigens by indirect immunofluorescence using monoclonal antibodies. Expectedly, the majority of these specimens expressed antigens known to be expressed on lymphoid, and not myeloid malignancies. These included the common acute lymphoblastic leukemia antigen (CALLA), the p32 B-cell associated antigen, and T-cell associated antigens. Leukemic cells from the 8 remaining patients expressed antigens known to be present on both myeloid and lymphoid leukemias. These included HLA/DR, and the antigens identified by BA-1 and BA-2. Cells from 2 of these 8 patients reacted with antibodies that define antigens present on normal and malignant myeloid cells. Both specimens reacted with 1G10, an anti-granulocyte antibody, and one reacted with 5F1 which reacts with monocytes, nucleated red blood cells, megakaryocytes and platelets. One of these patients relapsed while receiving ALL therapy, and the morphology of her leukemic cells became characteristic of acute monocytic leukemia (AMoL). The second patient failed ALL therapy but responded to standard acute nonlymphocytic leukemia (ANLL) therapy, clearing her peripheral blasts. Thus these studies confirm that cell surface phenotyping with monoclonal antibodies can recognize ALL cells that express myeloid rather than lymphoid associated antigens and demonstrate that the malignant cells display a clinical behavior consistent with the diagnosis of ANLL.
D000293:Adolescent; D000911:Antibodies, Monoclonal; D000941:Antigens / Q000276:immunology; D001215:Asparaginase / Q000627:therapeutic use; D002648:Child; D005260:Female; D005455:Fluorescent Antibody Technique; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000175:diagnosis* / Q000188:drug therapy; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000941:Antigens; D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone